Evidence map›Paper›PMID 23670354›Full record

Trial reportJournal of the renin-angiotensin-aldosterone system : JRAAS2015

Aliskiren improves vascular smooth muscle function in the skin microcirculation of type 2 diabetic patients with normal renal function.

Jody R Dushay, Francesco Tecilazich, Antonios Kafanas, Mary L Magargee, Michael E Auster, Charalambos Gnardellis, Thanh Dinh, Aristidis Veves

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jody R DushayDivision of Endocrinology, Beth Israel Deaconess Medical Center, USA.
Francesco TecilazichJoslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
Antonios KafanasJoslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
Mary L MagargeeJoslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
Michael E AusterJoslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
Charalambos GnardellisTechnological Educational Institute of Messolonghi, Greece.
Thanh DinhJoslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
Aristidis VevesJoslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA aveves@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USTechnological Educational Institute of Western Greece · GR

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1RR025758
6 · The paper itself

Abstract

objectiveThe objective of this paper is to study the effect of aliskiren on metabolic parameters and micro- and macrovascular reactivity in individuals diagnosed with or at high risk for developing type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND

methodsWe studied 47 T2DM and 41 at-risk individuals in a randomized, double-blinded, placebo-controlled trial. All subjects were treated with 150 mg aliskiren or placebo daily for 12 weeks. Twenty-six (55%) of T2DM and four (8%) at-risk subjects were also treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers.

resultsAliskiren treatment was associated with improvement in systolic and diastolic blood pressure and endothelium-independent vasodilation at the skin microcirculation in those with T2DM but not in those at risk. There were no incidences of hypotension and no significant changes in serum potassium or creatinine levels with aliskiren treatment in either study group.

conclusionsAliskiren improves blood pressure and vascular smooth muscle function in the skin microcirculation of T2DM patients.

Indexed as

Kidney Function TestsAmidesBiomarkersBiopsyDemographyDiabetes Mellitus, Type 2FemaleForearmFumaratesHumansInflammationMaleMicrocirculationMiddle AgedMuscle, Smooth, VascularSkinaliskirenAmidesBiomarkersFumaratesaliskirenprediabetesType 2 diabetesvascular smooth muscle

Identifiers

PMID23670354
PMCPMC5287335
OpenAlexW2154434254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.